Compare VCYT & PBLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VCYT | PBLS |
|---|---|---|
| Founded | 2006 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.4B |
| IPO Year | 2013 | 2026 |
| Metric | VCYT | PBLS |
|---|---|---|
| Price | $55.59 | $30.20 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $44.00 | N/A |
| AVG Volume (30 Days) | ★ 1.4M | 582.4K |
| Earning Date | 05-05-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 164.52 | N/A |
| EPS | ★ 0.35 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $13.76 | N/A |
| Revenue Next Year | $12.35 | N/A |
| P/E Ratio | $165.70 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $22.61 | $25.56 |
| 52 Week High | $60.91 | $30.19 |
| Indicator | VCYT | PBLS |
|---|---|---|
| Relative Strength Index (RSI) | 58.01 | 63.50 |
| Support Level | $40.27 | $26.68 |
| Resistance Level | N/A | $30.19 |
| Average True Range (ATR) | 2.80 | 2.38 |
| MACD | -0.26 | 0.24 |
| Stochastic Oscillator | 53.44 | 75.32 |
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder).
Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.